SCHEMBL4296769

SCHEMBL4296769

CC(C)(C)OC(=O)Nc1nn(-c2ccccc2)cc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.46
ATM Q13315 1/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HSD17B10 Q99714 1/20 0.44
HTT P42858 1/20 0.44
LMNA P02545 3/20 0.44
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
USP2 O75604 1/20 0.43
POLB P06746 1/20 0.43
RECQL P46063 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
AURKA O14965 5/20 0.42
TP53 P04637 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23789987 0.85 HDAC1 (0.49) L3MBTL1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL23928571 0.81 L3MBTL1 (0.61) L3MBTL1ATMMAPTALDH1A1SMN1; SMN2
SCHEMBL18379692 0.81 HTT (0.41) L3MBTL1ATMMAPTALDH1A1SMN1; SMN2
SCHEMBL16447788 0.80 PTGDR2 (0.40) KDM4ELMNAKMT2AMEN1GAA
SCHEMBL12291095 0.78 CNR2 (0.44) L3MBTL1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL6963566 0.78 BRD9 (0.48) MAPTALDH1A1SMN1; SMN2HPGDKDM4E
SCHEMBL1754340 0.77 HDAC1 (0.49) L3MBTL1MAPTALDH1A1SMN1; SMN2HPGD
SCHEMBL4398943 0.74 L3MBTL1 (0.46) L3MBTL1ATMMAPTALDH1A1SMN1; SMN2
SCHEMBL14237239 0.74 ALDH1A1 (0.49) L3MBTL1ATMMAPTALDH1A1SMN1; SMN2
SCHEMBL27660246 0.74 ALDH1A1 (0.49) L3MBTL1ATMMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
EP-2044055-A2 AMIDE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-08 EP disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 L3MBTL1 1367/4885ATM 3218/4885MAPT 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.